Chanelle Pharma, a prominent figure in Ireland's pharmaceutical industry, has undergone a significant transition with its acquisition by Exponent, a private equity firm. 

Founded by Michael H Burke in 1985, Chanelle Pharma has evolved into a global leader in the production of generic pharmaceuticals for both human and animal health. With over 730 employees across various locations, the company has established a strong foothold in Ireland, the UK, Europe, and Jordan.

The undisclosed acquisition marks a pivotal moment for Chanelle Pharma, signifying a strategic shift in ownership while retaining its commitment to growth and innovation. Exponent, renowned for its expertise in nurturing businesses, particularly in the European market, has demonstrated confidence in Chanelle Pharma's potential for expansion.

Michael H. Burke, the visionary behind Chanelle Pharma's success, expressed his confidence in Exponent's ability to steer the company towards new heights. His decision to relinquish ownership reflects a strategic move to facilitate the company's evolution under fresh leadership.

David McGovern, Partner at Exponent said, “We are delighted to invest in Chanelle, a company we have admired for a long time. Our investment in Chanelle demonstrates our commitment to partner with market leading Irish businesses seeking to grow internationally and accelerate their growth. We look forward to working closely with Chanelle’s management team to strengthen its global presence and invest in its capabilities. We applaud Michael’s leadership of the business and thank him for trusting us to take Chanelle forward.”

James Gunton, Partner at Exponent, underscored the company's commitment to building upon Chanelle Pharma's achievements, emphasizing a focus on product development and research initiatives. The acquisition heralds a new chapter for Chanelle Pharma, characterized by sustained innovation and market expansion.

With FDA approval for its Spot On manufacturing, Chanelle Pharma is poised for continued success in international markets.

The acquisition underscores Exponent's confidence in Chanelle Pharma's potential for growth and innovation. With a dedicated management team at the helm, Chanelle Pharma remains poised for continued success in the dynamic landscape of pharmaceuticals.